{"id":196956,"date":"2026-10-06T04:25:39","date_gmt":"2026-10-05T20:25:39","guid":{"rendered":"https:\/\/www.chinamoneynetwork.com\/?p=167799"},"modified":"2026-10-06T04:25:39","modified_gmt":"2026-10-05T20:25:39","slug":"global-collaboration-between-csl-and-alentis-to-develop-and-commercialize-lixudebart-for-treating-rare-kidney-and-liver-diseases","status":"publish","type":"post","link":"https:\/\/www.chinalegalblog.com\/en\/2026\/10\/06\/global-collaboration-between-csl-and-alentis-to-develop-and-commercialize-lixudebart-for-treating-rare-kidney-and-liver-diseases\/","title":{"rendered":"Global Collaboration Between CSL and Alentis to Develop and Commercialize Lixudebart for Treating Rare Kidney and Liver Diseases"},"content":{"rendered":"CSL and Alentis have announced a global partnership to collaborate on the development and commercialization of Lixudebart, a treatment for...","protected":false},"excerpt":{"rendered":"<p>CSL and Alentis have announced a global partnership to collaborate on the development and commercialization of Lixudebart, a treatment for&#8230;<\/p>\n","protected":false},"author":252,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[194,494,932],"tags":[14411,14412,14154,5256,10733,14413,14414,14415,12179,14416],"class_list":["post-196956","post","type-post","status-publish","format-standard","hentry","category-news-chinese-law","category-pharmaceutical","category-pharmaceutical-industry","tag-alentis","tag-csl","tag-global-collaboration","tag-healthcare","tag-industry","tag-kidney-diseases","tag-liver-diseases","tag-lixudebart","tag-medical-innovation","tag-rare-diseases"],"_links":{"self":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/196956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/users\/252"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/comments?post=196956"}],"version-history":[{"count":1,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/196956\/revisions"}],"predecessor-version":[{"id":196957,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/196956\/revisions\/196957"}],"wp:attachment":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/media?parent=196956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/categories?post=196956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/tags?post=196956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}